No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IMCR Immunocore
- 50.470
- -0.530-1.04%
Close May 22 16:00 ET
2.52BMarket Cap-41368P/E (TTM)
51.500High49.900Low1.84MVolume51.000Open51.000Pre Close93.50MTurnover5.04%Turnover RatioLossP/E (Static)50.01MShares76.98052wk High7.02P/B1.85BFloat Cap42.21052wk Low--Dividend TTM36.56MShs Float76.980Historical High--Div YieldTTM3.14%Amplitude18.430Historical Low50.700Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Offer Insights on Healthcare Companies: Cresco Labs (OtherCRLBF) and Immunocore Holdings (IMCR)
Optimistic Buy Rating for Immunocore Holdings Amid Promising Brenetafusp Study and Strategic Developments
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Immunocore Holdings (IMCR) and Madrigal Pharmaceuticals (MDGL)
Analysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX), Immunocore Holdings (IMCR) and Acadia Healthcare (ACHC)
Immunocore Holdings Is Maintained at Buy by Mizuho
Immunocore Holdings Is Maintained at Buy by Mizuho
Express News | Immunocore : Mizuho Cuts Target Price to $88 From $90
Comments
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
6
$United Therapeutics(UTHR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Liquidia(LQDA.US$ Phase 3
$United Therapeutics(UTHR.US$ Phase 3
$MorphoSys(MOR.US$ Phase 3
$Immunocore(IMCR.US$ Phase 3
$Crinetics(CRNX.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$AstraZeneca(AZN.US$ Phase 3
$Capricor Therapeutics(CAPR.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3...
10
1
Immunocore Holdings' P/S ratio aligns with industry peers, but its projected revenue growth lags behind sector-wide forecasts, indicating a potential realignment. Current market sentiment may be too optimistic, posing potential disappointment for investors if the P/S ratio follows the growth outlook.
JP Morgan predicts growth for Insmed due to recent study updates, potential rise of Denali shares ahead of 2025 readouts, and an upside for Immunocore shares following a 'strong' oncology drug launch. Crinetics could also benefit from upcoming catalysts.
Gainers:
In reaction to earnings/guidance:
• $The ODP(ODP.US$ +8.03% (The ODP Corporation gains on guiding Q2 and FY22 earnings above the consensus; to buyback shares of $600M)
• $Synchrony Financial(SYF.US$ +4.2%(The financial services company posted adjusted earnings per share of $1.60 for the June ended quarter, beating analysts' estimates of $1.41 per share, according to FactSet.)
• $Goldman Sachs(GS.US$ +4.2% (Goldman Sachs beats...
In reaction to earnings/guidance:
• $The ODP(ODP.US$ +8.03% (The ODP Corporation gains on guiding Q2 and FY22 earnings above the consensus; to buyback shares of $600M)
• $Synchrony Financial(SYF.US$ +4.2%(The financial services company posted adjusted earnings per share of $1.60 for the June ended quarter, beating analysts' estimates of $1.41 per share, according to FactSet.)
• $Goldman Sachs(GS.US$ +4.2% (Goldman Sachs beats...
14
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg